Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.755 +0.035 (+2.03%)
Streaming Delayed Price Updated: 1:52 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 Next >
News headline image
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027. 
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock ↗
 
Via Benzinga
News headline image
Forecasting The Future: 6 Analyst Projections For Lineage Cell Therapeutics ↗
 
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
 
Via Benzinga
News headline image
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Which stocks are moving after the closing bell on Wednesday? ↗
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
News headline image
The Analyst Verdict: Lineage Cell Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2025 ↗
 
Via Benzinga
News headline image
A Preview Of Lineage Cell Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
LCTX Stock Earnings: Lineage Cell Therapeutics Meets EPS, Beats Revenue for Q1 2024 ↗
LCTX stock results show that Lineage Cell Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023 ↗
LCTX stock results show that Lineage Cell Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 7, 2024 ↗
Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on revenue of $106.08 million. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.